Navigation Links
Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients
Date:12/10/2013

NORTHBROOK, Ill. and SAN DIEGO, Dec. 10, 2013 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), and Vical Incorporated (Nasdaq: VICL) today announced the initiation of a Phase 2 trial of ASP0113 in approximately 140 solid organ transplant (SOT) recipients.

The global, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy of ASP0113 compared to placebo as measured by the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. The study will also evaluate the safety of ASP0113 in this patient population. Follow-up for each subject will continue for one year following enrollment.

"Following the initiation of our Phase 3 trial of ASP0113 in hematopoietic cell transplant (HCT) recipients in June, we are pleased to expand the ASP0113 program with this Phase 2 trial in SOT recipients," said Bernie Zeiher, Senior Vice President and Global Therapeutic Area Head of Immunology and Infectious Diseases at Astellas Pharma Global Development, Inc. "The unmet medical need to control CMV in transplant recipients remains high."

"We are very pleased with the collaborative nature of our relationship with Astellas and with the progress being made," said Vijay Samant, President and Chief Executive Officer of Vical.

Astellas is conducting the trial under an exclusive worldwide license agreement with Vical to develop and commercialize ASP0113. Vical is providing development, regulatory and manufacturing support.

About ASP0113
ASP0113 (formerly TransVax™) is an investigational bivalent DNA vaccine containing plasmids (closed loops of
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
2. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
3. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
7. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
8. Astellas to Drive PGA TOURs New Womens Initiative
9. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
10. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
11. Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 01, 2015 Research and Markets ... "US ACO IT Spending Outlook 2018" report ... number of lives covered by ACO would grow at ... report, the ACO IT spending has been studied on ... software and spending on services. Our research provides current ...
(Date:5/1/2015)... Corporation (NASDAQ: THOR ), a world leader in mechanical ... announced today that Marta Antonucci has joined Thoratec ... This new Europe -based position is responsible ... America , including Europe , ... , and reports directly to the Chief Executive Officer. Following the ...
(Date:5/1/2015)... 2015  CytRx Corporation (CYTR), a biopharmaceutical research ... financial results for the three months ended March ... accomplishments and upcoming milestones for its clinical development ... the early months of 2015, including the announcement ... aldoxorubicin in patients with soft tissue sarcoma, and ...
Breaking Medicine Technology:United States ACO IT Spending Outlook 2014-2018 2Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11
... is natural that all customers using the services of online ... for them and getting their order within the shortest possible ... and well-taken. This site assures new and regular clients with ... security. It uses the most updated methods to make every ...
... HeartWare International, Inc. (Nasdaq: HTWR ) (ASX: ... support technologies that are revolutionizing the treatment of advanced ... scheduled to make an investor presentation at the Canaccord ... 2010 at 9:00 a.m. Pacific Time (noon, Eastern Time). ...
Cached Medicine Technology:A New Online Pharmacy rxbuys.com by RX Corp Offers its Services to International Clients 2HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2
(Date:5/3/2015)... ST. LOUIS, Missouri (PRWEB) May 03, 2015 ... in international business that will directly impact your ... (EMIB), is designed for dynamic leaders in multinational ... a multinational company. In a changing global landscape, ... business negotiations and relationships. The EMIB program develops ...
(Date:5/3/2015)... SpineFrontier, a Less Exposure Surgery (LES) technology ... and market their new sacroiliac joint fusion screw, the ... settings and is compatible with both lateral and alternate ... extensively researched and refined by SpineFrontier, the first company ... in conjunction with a sacroiliac joint fusion system like ...
(Date:5/3/2015)... HealthPostures, a pioneering ergonomics company ... appearance at the , May 5 - 7, 2015 ... exhibit at the conference include its bestselling TaskMate sit ... is the 6100 TaskMate Executive. Features of the 6100 ... keyboard tray, extended platform work surface and supply holders. ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... today, Saturday, May 2nd at the MGM Grand Garden Arena ... to secure tickets for both the actual fight and various ... wanted for more than five years was finally been agreed ... inside the ring to fight Manny “Pac-Man” Pacquiao in what ...
(Date:5/2/2015)... ” was featured on NewsWatch as part of its monthly ... applications on the market for iOS, Android, and Windows. Joe ... app review and shared with viewers how this app allows ... , In this material world, almost everything is about money. ... is why those things should be prioritized above others. And ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2
... children in Ecuador whose mothers were exposed to pesticides while ... copy geometric figures as compared to a control group. This ... issue of Paediatrics. ,Philippe Grandjean, ... led a team of researchers and analyzed data on 72 ...
... who have a slower rate of caffeine metabolism as ... increased risk //for development of non-fatal heart attack, following ... most important source of caffeine and deserves the credit ... worldwide. Several studies have highlighted the possibility of cardiovascular ...
... South Dakota signed a law banning abortions, which may be ... which may trigger national debate. // ,The law ... decision, known as Roe vs. Wade, that made it legal ... ,Governor Mike Rounds, a member of President George W. ...
... The cost of treatment at the community-built Riverina Cancer Care ... around reduction in prices, which will bring about the much ... happened following fears expressed by the cancer support groups that ... Hull, who is the Federal Member for Riverina, is hopeful ...
... on the plane to the gulf, not so much for greener ... Gulf. // The demand for rabbit meat has increased following the ... desert, for what was a dry gulf palate sans the chicken. ... meat and this has led to several enquiries flooding the State ...
... birth defects is improved by incorporation of folic acid in ... been known that folic acid supplementation during pregnancy can reduce ... anencephaly etc. ,The researchers analyzed the effect of ... born with spina bifida between the year 1998 and 2001. ...
Cached Medicine News:
Expert QC data management solution...
The AVOXimeter 1000E measures:, Oxygen saturation (for diagnosing shunts) , Oxygen content (for Fick Principle calculations), Total hemoglobin concentration , ,Ideal for adult and pediatri...
Inquire...
... visual field is examined with an ocular ... overlapping the ocular fundus image and the ... between the two., ,The data integrates with ... to totally manage the fundus images and ...
Medicine Products: